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The Athlome Project Consortium* 48 
 49 
Despite numerous attempts to discover genetic variants associated with elite athletic 50 
performance, injury predisposition and elite/world-class athletic status, there has been limited 51 
progress to date. Past reliance on candidate gene studies predominantly focusing on genotyping a 52 
limited number of single nucleotide polymorphisms (SNPs) or the insertion/deletion variants in 53 
small, often heterogeneous cohorts (i.e., made up of athletes of quite different sport specialties) 54 
have not generated the kind of results that could offer solid opportunities to bridge the gap 55 
between basic research in exercise sciences and deliverables in biomedicine. A retrospective 56 
view of genetic association studies with complex disease traits indicates that transition to 57 
hypothesis-free genome-wide approaches will be more fruitful. In studies of complex disease, it 58 
is well recognized that the magnitude of genetic association is often smaller than initially 59 
anticipated and, as such, large sample sizes are required to identify the gene effects robustly. 60 
Thus, alternative large-scale, collaborative efforts involving well-phenotyped male and female 61 
cohorts from which high-resolution genome-wide data is generated and interrogated using 62 
advanced bioinformatics approaches are necessary for meaningful progress to be made. 63 
Accordingly, a symposium was held in Athens and on the Greek island of Santorini from 14-17th 64 
May 2015 (http://celebratorysymposium.net) to review the main findings in exercise genetics and 65 
genomics and to explore promising trends and possibilities. The symposium also offered a forum 66 
for the development of a position stand (the Santorini Declaration). Among the participants, 67 
many were involved in ongoing collaborative studies (e.g., GAMES, Gene SMART, GENESIS 68 
and POWERGENE). A consensus emerged among participants that it would be advantageous to 69 
bring together all current studies and those recently launched into one new large collaborative 70 
initiative, which was subsequently named the Athlome Project Consortium.  71 
 72 
At the outset, the Athlome Project aims to collectively study the genotype and phenotype data 73 
currently available on elite athletes, in adaptation to exercise training (in both human and animal 74 
models) and on exercise-related musculoskeletal injuries from individual studies and from 75 
consortia worldwide. To achieve this, several steps are set out:  76 
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 77 
1. To establish an ethically sound international research consortium (Athlome Project 78 
Consortium) and biobank resource systematically across individual centres; 79 
2. To discover genetic variants associated with exercise performance, adaptive response to 80 
exercise-training, and skeletal-muscle injuries using the genome-wide association study 81 
(GWAS) approach, targeted sequencing or whole genome sequencing, where possible; 82 
3. To validate and replicate the genetic markers from the discovery phase across sex and 83 
ethnicity; and 84 
4. To conduct functional investigations following replicated findings (e.g., study the 85 
replicated SNPs and their linkage disequilibrium regions, in vitro expression studies and 86 
knockouts of nearby genes) to better understand the associated biology. 87 
 88 
During the development of the initial phase of the Athlome Project in determining the genetic 89 
variations related to elite athletic performance and injury predisposition, epigenomic, 90 
transcriptomic and proteomic analyses need also be carefully planned to strengthen the 91 
understanding of gene functions. Linking these findings with metabolic profiling (the end 92 
products of the cellular processes) is also a future aspiration of the Athlome Project. Another 93 
challenge is to be able to efficiently integrate the multiple “omics” datasets generated from the 94 
different approaches. The ultimate goal of the Athlome Project Consortium is to generate the 95 
ethically sound environment, interest and capacity needed to develop the specialist knowledge to 96 
inform personalized training and injury prevention, as well as doping detection. The following 97 
individual or collaborative studies have agreed to work together in the global partnership that 98 
constitutes the Athlome Project Consortium. The participating cohorts and the focus of each are 99 
depicted in Figure 1. 100 
  101 
Eastern Europe population studies (The Russian and Belarusian cohorts, GELAK, 102 
GELAV, and GUAP) 103 
The Russian and Belarusian cohorts, the Genetics and Epigenetics of Lithuanian Athletes from 104 
Kaunas (GELAK) and Vilnius (GELAV), and the Genome of Ukrainian Athletes Project 105 
(GUAP) have consolidated to identify genetic and epigenetic variations associated with high-106 
level sports performance. The cohort comprises East Europeans (from Belarus, Lithuania, 107 
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Russia, and Ukraine; in total n = 8,228 athletes and n = 4,121 controls). The athletes are grouped 108 
into international (including participants in Olympics and World Championships), national, 109 
regional, or local/non-competitive categories. These include biathletes, distance runners, cyclists, 110 
triathletes, kayakers, rowers, canoers, modern pentathletes, orienteers, skiers, speed skaters, 111 
short-trackers, walkers, weightlifters, bodybuilders, powerlifters, strongmen, sprint runners (≤ 112 
400 m), sprint swimmers (50 - 100 m), decathletes, heptathletes, combat athletes, field athletes, 113 
bobsleigh athletes, rhythmic and artistic gymnasts, figure skaters, fencers and team ball-sport 114 
players. A portion of the participants have been evaluated with a variety of quantitative 115 
performance- and health-related assessments, including strength/power-related measurements, 116 
agility/speed-related measurements, balance, flexibility and coordination measurements, 117 
endurance-related measurement, skeletal muscle biopsy, and health-related measurements. 118 
 119 
Principal Investigators: Ildus I Ahmetov (Volga Region State Academy of Physical Culture, 120 
Sport and Tourism, RUS), Svitlana B Drozdovska (National University of Physical Education of 121 
Ukraine, UKR), Colin N Moran (University of Stirling, GBR), Valentina Ginevičienė (Vilnius 122 
University, LTU), Andrei A Gilep (Institute of Bioorganic Chemistry NASB, BLR). 123 
 124 
ELITE elite.stanford.edu 125 
The Exercise at the Limit – Inherited Traits of Endurance (ELITE) consortium is a global 126 
initiative with the main objective to map the role that genetics plays in athletic ability versus 127 
environmental factors, such as training. Study participant (n > 500) selection is based on a 128 
physiological variable relevant for both health and sport performance, i.e., maximum oxygen 129 
uptake (V̇O2max). The main inclusion criterion is V̇O2max > 75 ml/kg/min for men and > 63 130 
ml/kg/min for women, respectively. The consortium is continuously expanding and is recruiting 131 
athletes from all over the globe (with main focus on Caucasians, North East Africans, East 132 
Asians and South Americans) who are successful in endurance sports (running, cycling, cross 133 
country skiing, triathlon, and rowing). Analyses currently include enhanced whole exome 134 
sequencing and GWAS (1.7 million SNPs). The combination of analytic methods will enable 135 
findings and differentiation between common variants with small effects and novel rare variants 136 
with larger effects. The aim is also to investigate gender and ethnic differences. 137 
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Principal Investigators: Euan A Ashley, C Mikael Mattsson, Matthew Wheeler, Daryl Waggott 138 
(Stanford University, USA). 139 
 140 
Elite East African athlete cohort 141 
The consortium also aims to study the East African running success by analyzing data from 142 
previously recruited subjects: (i) 76 endurance runners (64 men) and 38 sprint and power event 143 
athletes (18 men) from the Ethiopian national athletics teams, 315 controls from the general 144 
Ethiopian population (281 men), 93 controls from the Arsi region of Ethiopia (80 men) and (ii) 145 
291 elite Kenyan endurance athletes (232 men) and 85 control participants (40 men). Seventy 146 
(59 men) Kenyan athletes had competed internationally and achieved outstanding success. 147 
 148 
Principal Investigators: Yannis Pitsiladis (University of Brighton, GBR), Robert Scott 149 
(University of Cambridge, GBR). 150 
 151 
GAMES 152 
An international consortium (GAMES) was established to compare allele frequencies between 153 
elite endurance athletes and ethnicity-matched controls. GWASs were undertaken on two cohorts 154 
of elite endurance athletes (GENATHLETE and Japanese endurance runners) and their 155 
respective controls, from which a panel of 45 candidate SNPs was identified. These markers 156 
were tested for replication in seven additional cohorts of endurance athletes and controls from 157 
Australia, Ethiopia, Japan, Kenya, Poland, Russia and Spain. The study is based on a total of 158 
1,520 endurance athletes (835 of them had competed in World Championships or Olympic 159 
Games) and 2,760 controls. 160 
 161 
Principal Investigators: Claude Bouchard, Tuomo Rankinen (Pennington Biomedical Research 162 
Centre, Louisiana State University, USA), Noriyuki Fuku (Juntendo University, JPN), Yannis 163 
Pitsiladis (University of Brighton, GBR), Bernd Wolfarth (Humboldt University, DEU), 164 
Alejandro Lucia (Universidad Europea de Madrid, SP). 165 
 166 
GENATHLETE 167 
The study was launched in 1993 with the aim of identifying DNA variants that are present at 168 
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different frequencies between elite endurance athletes and sedentary controls. Male endurance 169 
athletes and controls were recruited from Canada, Finland, Germany and the USA. The cohort 170 
assembled to date includes 315 elite endurance athletes and 320 matched controls. Selection 171 
criteria for the all-male endurance athlete sample include that they had to be athletes of national 172 
or international caliber with a V̇O2max of at least 75 ml/kg/min. The mean value for the 315 173 
athletes is currently 79 ml/kg/min while the mean for the 320 control subjects reached 40 174 
ml/kg/min. Multiple candidate genes have been studied using the resources of GENATHLETE. 175 
A genome-wide screen for common variants has been performed on GENATHLETE (see 176 
GAMES cohort above) and further studies are focusing on nuclear and mitochondrial DNA 177 
sequencing. 178 
  179 
Principal Investigators: Claude Bouchard, Tuomo Rankinen (Pennington Biomedical Research 180 
Centre, Louisiana State University System, USA), Bernd Wolfarth (Department of Sports 181 
Medicine, Charite Medical School, Berlin, Germany), Louis Perusse (Laval University, Quebec, 182 
Canada), Rainer Rauramaa (University of Eastern Finland, Kuopio, Finland). 183 
 184 
GENESIS 185 
The GENetics of Elite Status In Sport (GENESIS) consortium aims to identify molecular genetic 186 
characteristics associated with successful sports performance. The cohort (current n > 1,200) is 187 
mainly composed of UK athletes. Sports include marathon running and other track-and-field 188 
athletics, cycling and team sports (e.g. soccer).  The RugbyGene Study is a major subcomponent 189 
of GENESIS and focuses on rugby (both union and league codes). Objectives of GENESIS are: 190 
(i) to increase current cohort size substantially; (ii) to apply hypothesis-free approaches to 191 
identify molecular genomic markers; (iii) to expand GENESIS from genomics to other “omics”; 192 
and (iv) to combine the “omics” data with athlete health and performance data to maximize 193 
practical impact of GENESIS. 194 
 195 
Principal Investigators: Alun G Williams, Stephen H Day, Georgina K Stebbings (Manchester 196 
Metropolitan University, GBR), Robert M Erskine (Liverpool John Moores University, GBR), 197 
Hugh E Montgomery (University College London, GBR). 198 
 199 
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Gene SMART Study www.vu.edu.au/speed-gene 200 
The Gene SMART (Skeletal Muscle Adaptive Response to Training) study aims to identify the 201 
gene variants that predict the skeletal muscle response to both a single bout and 4 weeks of High-202 
Intensity Interval Training (HIIT) in three different training centres. While the lead training and 203 
testing centre is located in Victoria University, Melbourne, two other centres have been launched 204 
at Bond University, Australia and the University of Sao Paulo, Brazil. A fourth centre 205 
(University of Brighton, UK) will focus on the omics analyses. The cohort is comprised of 206 
moderately-trained, healthy male participants (aged 20-45 years, body mass index ≤ 30 kg/m2). 207 
Participants are undergoing similar exercise testing and exercise training in three different 208 
laboratories. Dietary habits are assessed by questionnaire and nutritionist consultation. Activity 209 
history is assessed by questionnaire and current activity level is assessed by activity monitoring. 210 
A number of muscle and blood analyses are to be performed, including genotyping, 211 
mitochondrial respiration, transcriptomics, proteomics, and enzymes activity before, during and 212 
after training, where appropriate. Currently ~40 participants have finished the study and the aim 213 
is to train a total of 250 participants. The Gene SMART also includes baseline and post-training 214 
testing and sampling for all participants.  215 
 216 
Principal Investigators: David Bishop, Nir Eynon (Victoria University, AUS). 217 
 218 
GOINg  219 
The recently established Genomics Of INjuries (GOINg) consortium aims to identify DNA 220 
variants that modify the risk of anterior cruciate ligament (ACL) injuries. It is the only 221 
consortium within the Athlome Project to specifically investigate exercise-associated 222 
musculoskeletal injuries. The plan is to screen current known loci for ACL injury susceptibility 223 
in larger data sets in an attempt to determine if they remain as susceptibility loci across all 224 
populations using the hypothesis-driven candidate gene case-control study design. Care will be 225 
taken to use the same criteria to accurately phenotype, with respect to ancestry, sporting and 226 
occupational details, injury profile and mechanism(s) of injury, other injury history and family 227 
history, as well as, other appropriate medical history and medication use. The actual functional 228 
significance of the identified variants will also be investigated. This initial phase will be 229 
followed by sequencing and the research objectives will be eventually expanded to include other 230 
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“omics”. Thus far, ACL rupture consortium has collected DNA samples and clinical, as well as 231 
physical and occupational activity information from subjects from South Africa, Poland, 232 
Australia, Russia and Italy. 233 
 234 
Principal Investigators: Malcolm Collins, Alison September, Michael Posthumus (University of 235 
Cape Town, ZAF), Nir Eynon (Victoria University, AUS), Pawel Cieszczyk (University of 236 
Szczecin, POL). 237 
 238 
J-HAP 239 
The Japanese Human Athlome Project (J-HAP) focuses on the study of genes associated with 240 
physical performance and its related phenotypes (e.g., muscle mass, muscle fiber type, V̇O2max). 241 
The cohort is comprised of Japanese athletes (currently > 2,400, mainly international and 242 
national levels) and healthy Japanese controls (currently > 1,000). These athletes are mainly 243 
track-and-field athletes and swimmers competing in endurance- and sprint/power-oriented events. 244 
Multiple “omics” approaches will be used to determine genes in talent identification in the 245 
Japanese population. Among the collected Japanese athletes’ and controls’ samples, 246 
approximately 200 muscle biopsies were obtained from both athletes and controls in order to 247 
investigate genetic variants associated with muscle fibre type distribution. 248 
 249 
Primary Investigators: Noriyuki Fuku (Juntendo University, JPN), Naoki Kikuchi (Nippon Sport 250 
Science University, JPN), Eri Miyamoto-Mikami (The National Institute of Fitness and Sports in 251 
Kanoya, JPN). 252 
 253 
NTR  254 
The Netherlands Twin Register (NTR) is a population-based cohort recruiting both newborn and 255 
adult multiples and their family members with continuous longitudinal data collection. In the 256 
past 25+ years, around 40% of all twins and multiples in the Netherlands have taken part in the 257 
NTR research projects. Family members and spouses of twins also took part, leading to a total of 258 
over 185,000 participants across multiple research projects. The longitudinal information that has 259 
been collected extends from genotype to biomarkers, gene expression to rich behavioral 260 
information including biennial reports on (competitive) sports participation and performance 261 
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level and on injuries related to sports. In its sports research track, NTR aims to understand the 262 
interplay between genetic and environmental factors shaping individual differences in sports 263 
participation and performance. In the NTR, participants are recruited as newborns and followed 264 
into young adulthood, 520 have played competitively at a regional and 189 at a national level. 265 
Main sports that Dutch adolescents/young adults engage in are swimming, tennis, bicycling, 266 
soccer and field hockey. The longitudinal data collection of the NTR is ongoing and securely 267 
funded for the next 5 years. 268 
 269 
Principal Investigators: Eco de Geus, Meike Bartels (VU University and VU medical centre, 270 
NLD). 271 
 272 
POWERGENE 273 
The POWERGENE consortium aims to characterise the elite sprint/power athlete genotype. The 274 
internationally competitive (Olympic/Word championship qualifiers) sprint/power athletes are 275 
from: Australia, Belgium, Greece, Italy, Jamaica, Japan, Lithuania, Poland, Spain, the U.S.A., 276 
Brazil, and Russia. They will be compared with sub-elite athletes (national qualifiers), endurance 277 
athletes, team athletes and controls. The current cohort consists of female (n = 264) and male (n 278 
= 481) specialist power athletes across three major ethnicities (i.e., European, West African and 279 
East Asian ancestries). Sprint/power athletes include those individuals competing in track (≤ 800 280 
m) and field (jump, throw) events, cycling (track), swimming (≤ 200 m), gymnastics (artistic), 281 
weightlifting, judo, speed-skating and power lifting. Endurance athletes (n = 586) include track 282 
and road running specialists (> 800 m), rowers, cyclists, swimmers (> 200 m), triathletes and 283 
ironmen. Team sports (n = 862) include football (soccer), cricket, hockey, volleyball and 284 
basketball.  285 
 286 
Principal Investigators: Yannis Pitsiladis (University of Brighton, GBR), Kathryn North 287 
(Murdoch Childrens Research Institute, AUS), Nir Eynon (Victoria University, AUS). 288 
 289 
Super-athletes: Genes and Sweat 290 
The study aims to (i) identify genetic variants associated with elite athletic performance, (ii) 291 
study potential ethnic differences, and (iii) study the functional significance of the identified 292 
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variants. A GWAS will be carried out in 3,000 consented elite athletes, tested negative for 293 
doping substances at the Anti-Doping Laboratories, Federazione Medico Sportiva Italiana 294 
(FMSI) and Anti-Doping Lab Qatar (ADLQ), using Illumina genotyping technologies. 295 
Examining genotype frequency distribution of elite athletes from European countries (where 296 
most of FMSI samples will be obtained) against those from South Asian and African countries 297 
(where most of ADLQ samples are expected to be obtained) would help to identify potential 298 
ethnic differences in the genetic predisposition to athletic performance. Subsequently, urine 299 
metabolome in a subset of these athletes (1,000 subjects) will be performed, and will be related 300 
to the athlete’s sporting discipline.  301 
 302 
Principal Investigators: Mohamed El-Rayess, Costas Georgakopoulos, Mohammed Alsayrafi 303 
(ADLQ, QAT), Francesco Botre (FMSI, ITA), Karsten Suhre (Weill Cornell Medical College in 304 
Qatar, QAT), Mike Hubank (University College London, GBR). 305 
 306 
Epigenetics of Elite Athletic Performance 307 
It is clear from animal and human studies that epigenetic marks play a role in the modulation of 308 
gene expression in relevant tissues. There also are indications that epigenetic marks can be 309 
altered by acute and chronic exercise in skeletal muscle and adipose tissue where they have been 310 
studied. Thus individual differences in any exercise-related traits can potentially be explained by 311 
not only the impact of DNA sequence variation on biology and behavior but also by the effects 312 
of epigenomic signaling on gene expression. We are formulating the hypothesis that elite athletic 313 
performance is influenced by epigenomic alterations, facilitating morphological, physiological, 314 
metabolic, cognitive, emotional and behavioral changes that empower the athlete to push 315 
performance beyond existing boundaries. We envisage testing this hypothesis by recruiting twin 316 
athletes competing at the Olympic or World Championship levels.  317 
 318 
Principal Investigators: Vassilis Klissouras (University of Athens, GRC), Yannis Pitsiladis 319 
(University of Brighton, GBR). 320 
 321 
Rat models of exercise and health (LCR-HCR rat model)                           322 
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The purpose of the Low Capacity Rats-High Capacity Rats (LCR-HCR) model is to serve as a 323 
resource for the in-depth study of rat models to resolve the extremes of exercise and health. By 324 
connecting clinical observation with a theoretical base, the working hypothesis is that: variation 325 
in capacity for energy transfer is the central mechanistic determinant between disease and 326 
health (energy transfer hypothesis). As an unbiased test of this hypothesis, this study showed that 327 
two-way artificial selective breeding of rats for low and high intrinsic endurance exercise 328 
capacity also produced rats that differed for numerous disease risks, including the metabolic 329 
syndrome, premature aging, fatty liver disease, obesity, and Alzheimer’s disease. Exercise 330 
capacity is a result of intrinsic capacity plus adaptation to all aspects of physical activity.  To 331 
capture this biology, rats for low and high response to 8 weeks of treadmill running exercise 332 
were selectively bred. Thus, the study has models that represent the 4 “corners” of exercise 333 
capacity. These contrasting animal model systems may prove to be translationally superior 334 
relative to more widely used simplistic models for understanding disease conditions.  The rat 335 
models may be deeply explored to discover causal mechanisms and develop effective 336 
therapeutics.  These rats are being studied at over 50 institutions in 11 countries.   337 
 338 
Principal Investigators: Steven Britton, Lauren Koch (University of Michigan, USA). 339 
 340 
1000 Athlome Project  341 
The 1000 Athlome Project aims to sequence 1000 genomes of sprinters and distance runners of 342 
West and East African descent. Phase 1 of the project has already commended and involves the 343 
sequencing of 12 sprinters and 12 distance runners of the highest level (i.e. world record holders, 344 
Olympians and World Champions). Phase 2 (2016-2018) will involve increasing the sample size 345 
for sequencing to 100 genomes. The pool of the runners to be sequenced will be expanded to 346 
1000 by 2020 (Phase 3). An important aim of this sequencing project is to document the 347 
genotype distribution of elite east and west African athletes. The large amount of genotype data 348 
to be generated from the 1000 Athlome project will serve 1) as a reference panel for future 349 
performance studies, and 2) to guide other extreme phenotype studies in medical science.  350 
 351 
Principal Investigators: Masashi Tanaka (Tokyo Metropolitan Institute of Gerontology, JPN), 352 
Yannis Pitsiladis (University of Brighton, GBR). 353 
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 354 
Ethical Principles for Athlome biobanking 355 
The rise of biobanking has brought about a whole range of issues that are not all wholly relevant 356 
to the Athlome project. Nevertheless, certain key principles must be noted here that will inform 357 
the governance framework for Athlome: (i) the consortia are global in reach but there is no 358 
universal agreement on the precise nature of ethically justifiable governance for biobanking; (ii) 359 
given the globality of the consortia, no single regional (e.g., European, American) framework 360 
ought to be adopted; (iii) a general framework drawing on widely shared principles should be 361 
discussed and adopted. Chief among the concerns, but only one among several, is the problem of 362 
consent.   363 
 364 
Each of the projects that comprise Athlome are existing bio-guardians with a duty to protect the 365 
rights of participants who have contributed their samples to the individual projects noted above. 366 
The collection, storage, access to and use by researchers of those samples has been approved by 367 
relevant regulatory authorities (e.g., IRBs, RECs National Health Services Research Ethics 368 
Services) appropriate to the lead institution of the individual projects/consortia. Existing 369 
procedures do not currently extend to the sharing of samples beyond the study, since consent 370 
models are prospective (i.e. they guide future actions of researchers) and typically entail a form 371 
of specificity and the specific consent obtained varies between project partners. No retrospective 372 
consent is feasible and this is a widely shared problem for biobank development.  Since the form 373 
of collaboration Athlome envisages was not laid out before participants gave their consent, it 374 
might be concluded that the sharing of data beyond the original research group and its stated 375 
purposes invalidates that consent. The problem for Athlome is not an uncommon one for biobank 376 
collaborations since it seeks retrospective extension of the consent model.   377 
 378 
An ethical solution to this problem and related consent problems for new participants is to 379 
consider the use of a technique such as “broad consent”. The nomenclature here is important 380 
since this notion is variously described as “broad consent”, “blanket consent”, “future consent”, 381 
“hypothetical consent”, “passive/tacit/silent consent”, or “waived consent” (4,5). This would 382 
entail asking participants to agree to future unspecified uses of their data that are 383 
und(er)determined in the consent process and relevant forms (6). Without sufficient grasp of the 384 
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uses of the data or with whom it might be shared, this process fails the test of “comprehension” a 385 
user must understand sufficiently what they are agreeing to (3). Another possibility going 386 
forward would be “meta-consent” where consent is sought for broad categories of unspecified 387 
future research (7,8). Others have argued with respect to biobanking that the ethical issues 388 
entailed (e.g., privacy, confidentiality, ownership of access to the data) may be sufficiently 389 
assuaged by rigorous anonymization (1) and associated practices of data storage, though this is 390 
far from universally agreed upon (2). 391 
 392 
The Athlome project will develop principles and protocols for safeguarding participants rights to 393 
access, confidentiality, privacy of data, and assurances that there is no significant mission drift of 394 
the kind of which is permitted under some conceptions of broad consent (or its similes).  This 395 
would, for example, prohibit commercialization of participants’ data. In order to preserve the 396 
integrity of this process and the principles, rigorous anonymisation processes will be developed 397 
by a partner institution that does not have any direct role in data collection, storage or analysis.  398 
This will assure independence and integrity to the process. This is especially important in this 399 
case since some of the research participants are public figures, which increases the likelihood 400 
that someone might be interested in re-identifying their data and genomic sequences. The 401 
independent institution would also have an oversight of each new proposal for the Athlome 402 
project going forward in order to ensure compliance with those principles and protocols. 403 
 404 
In conclusion, by presenting the main study cohorts and projects that are currently included in 405 
the Athlome consortium it is our intention to show a global view not only of the main studies and 406 
initiatives that will be performed in the foreseeable future in the field of sports genomics (and 407 
that are likely to provide new exciting findings); we also wish to motivate potential collaboration 408 
initiatives with other research groups worldwide. International collaborations are likely to go 409 
well beyond the study of sports performance per se. Indeed, the Athlome consortium presents a 410 
unique chance to study the biology of the best elite athletes across most ethnicities, which is 411 
profoundly interesting from a medical point of view. World-class athletes represent the actual 412 
end-point of the human continuum of fitness-related phenotypes. In this regard, there is growing 413 
evidence (coming from both human and rodent study approaches – such as those included in the 414 
consortium) that not only physical activity levels but also individual fitness levels (a trait which 415 
14 
 
has a strong genetic component independent of activity levels) are inversely associated with the 416 
risk of major cardiometabolic diseases of western civilization, several cancer types and 417 
Alzheimer’s disease. Thus, studying the genes of elite athletes offers a unique chance to gain 418 
insight into important medical, including genetic predisposition (or resilience) to chronic disease. 419 
Indeed, the “rare-common” strategy, underpinned by ethically sound research governance, is a 420 
valuable approach model to examine general mechanisms of disease pathophysiology, with 421 
world-class athletes representing the “rare” (“super-fit”) human phenotype. Finally, identifying 422 
genetic markers of exercise capacity, adaptation to exercise programmes and in the 423 
predisposition to injury is certain to provide useful information to prescribe personalised exercise 424 
interventions in the context of 21st century medicine, which should not be based only on 425 
identifying new drug targets but also on implementing lifestyle interventions for disease 426 
prevention at the individual level.   427 
 428 
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Figure Legends: 670 
 671 
Figure 1. The Athlome Project Consortium. Genomic, epigenomic, transcriptomic, proteomic 672 
and metabolomic studies are being conducted by the participating centres to address questions in 673 
the three main research areas: elite performance, training response, and injury. Future 674 
investigations planned include genetically modified studies. 675 
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